Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Dec 12, 2023 4:36pm
91 Views
Post# 35780823

RE:RE:RE:RE:2023

RE:RE:RE:RE:2023Good  question.  See that some  folks  are selling  out  and the ASK  has dropped  from  25   to  15  to  now  10.

Mybe some year end tax selling  in here.  At thses prices,  maybe the insiders  are  buying  up all they can  to   take this  private  and  run with it.   Even though the assets are  questionable  at this time  . maybe they know  something  the retail  old timers do not!   Taking it private  , they  could sell some assets  and  then vend in  another project  and maybe turn this around without gong through all the  paperwork  to start a new  company.

Who really  knows  but I guess the hope of a near term announcement  prompted by the  larger volume last week  is not going to happen  and  maybe someone  just  wanted to get what they  could and the  insiders  bought
I  would be very dissapointed at them  going  private at these prices  -  but  not  surprised  once they  get  a  big enough  percentage of the  outstanding  shares   or  maybe a  'take over offer'  is coming  from someone else to do the same  thing.

At this point  , I  think we will have to wait until  next  year!!

GLTA

<< Previous
Bullboard Posts
Next >>